Buchumschlag

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Yewan Park, Jooyi Jung, Gi‐Ae Kim
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
von: Yewan Park, et al.
Veröffentlicht: (2024)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing?
von: Qiang Hu, et al.
Veröffentlicht: (2024)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
von: Nobuharu Tamaki, et al.
Veröffentlicht: (2025)

Editorial: Implementing Risk Assessment Tools for MetALD in Clinical Practice—Authors' Reply
von: Nikolaj Torp, et al.
Veröffentlicht: (2025)

Editorial: MetALD and Risk of Gastrointestinal Cancer—What Can We Learn From Japan?
von: Hannes Hagström, et al.
Veröffentlicht: (2025)

Letter on ‘Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study’
von: Muhammad Abubakr, et al.
Veröffentlicht: (2025)

Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study
von: Federica Tavaglione, et al.
Veröffentlicht: (2025)

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population
von: Carolin V. Schneider, et al.
Veröffentlicht: (2024)

Persistent Binge Drinking History Associated With Advanced Liver Fibrosis and All‐Cause Mortality in MetALD
von: Zhe‐Kun Xiong, et al.
Veröffentlicht: (2025)

Editorial: M et ALD and Risk of Gastrointestinal Cancer—What Can We Learn From Japan? Authors' Reply
von: Nobuharu Tamaki, et al.
Veröffentlicht: (2025)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply
von: Mohamed El‐Kassas, et al.
Veröffentlicht: (2025)

Letter: Clarifying the Synergistic Mechanisms of Mediterranean Diet and Time‐Restricted Feeding in MASLD Management—Authors' Reply
von: Sofia Tsitsou, et al.
Veröffentlicht: (2025)

Letter: Toward Intra‐Class Switching With JAK Inhibitors? Authors' Reply
von: Shintaro Akiyama, et al.
Veröffentlicht: (2025)

Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD —Insights From a National Analysis. Authors' Reply
von: Donghee Kim, et al.
Veröffentlicht: (2025)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
von: Stuart McPherson, et al.
Veröffentlicht: (2024)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
von: Virginia Solitano, et al.
Veröffentlicht: (2024)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
von: J. M. Schattenberg, et al.
Veröffentlicht: (2026)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition? Authors' Reply
von: Irene Spinelli, et al.
Veröffentlicht: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
von: Francisco Idalsoaga, et al.
Veröffentlicht: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
von: Fai Fai Ho, et al.
Veröffentlicht: (2025)

Letter: Is Enteric Neuropathy Absent in Hypermobility Spectrum Disorders/Hypermobile Ehler–Danlos Syndrome? Authors' Reply
von: Kim W. E. Sweerts, et al.
Veröffentlicht: (2025)

Letter: Dose and Donor Matter—Determining the Optimal Strategy for Faecal Microbiota Transplantation in Clostridioides difficile Infection. Authors' Reply
von: Sara Ellegaard Paaske, et al.
Veröffentlicht: (2026)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
von: Nina Dominik, et al.
Veröffentlicht: (2024)

Letter Regarding ‘Combined Lyon and Milan Scores Predict Gerd Management Outcome Better Than Either Score Alone or Their Individual Components’. Authors' Reply
von: Stefano Siboni, et al.
Veröffentlicht: (2025)

Editorial: Breath Profiling in MASLD—A Step Towards Better Risk Stratification
von: Takefumi Kimura
Veröffentlicht: (2025)

Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis? Authors' Reply
von: Hong‐Li Liu, et al.
Veröffentlicht: (2026)

Letter: Beyond Association—Operationalising PRS ‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
von: Yu‐Sheng Lin, et al.
Veröffentlicht: (2026)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
von: Yuki Utakata, et al.
Veröffentlicht: (2026)

Letter: Enhancing Risk‐Adapted Colorectal Cancer Screening for People With Diabetes—Authors' Reply
von: Teresa Seum, et al.
Veröffentlicht: (2025)

Editorial: Beyond Clinical Trials—Real‐World Data Suggest Usefulness of GLP‐1 RAs in MASLD Treatment. Authors' Reply
von: Chia‐Chih Kuo, et al.
Veröffentlicht: (2025)

Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination. Authors' Reply
von: Anupam Kumar Singh, et al.
Veröffentlicht: (2026)

Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply
von: Pinelopi Arvaniti, et al.
Veröffentlicht: (2025)

Letter: Addressing Gaps in Hospital‐Based Hepatitis C Screening—Insights and Recommendations. Authors' Reply'
von: Alberto Ferrarese, et al.
Veröffentlicht: (2025)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
von: Lukas Burghart, et al.
Veröffentlicht: (2026)

Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis. Authors' Reply
von: Chachrit Khunsriraksakul, et al.
Veröffentlicht: (2025)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV—Authors' Reply
von: Juan Macias, et al.
Veröffentlicht: (2025)

Editorial: Remission Ambition—How Far Should We Push in Older Adults? Authors' Reply
von: Catherine Z. Tang, et al.
Veröffentlicht: (2025)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply
von: Isabel Carbery, et al.
Veröffentlicht: (2024)

Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease—Need More Evidence. Authors' Reply
von: Jianhui Zhao, et al.
Veröffentlicht: (2024)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease—Author's Reply
von: Eunice Yewon Lee, et al.
Veröffentlicht: (2024)